Login to Your Account

Karo Bio Rises on Eprotirome Phase IIb Data in Dyslipidemia

By Cormac Sheridan

Wednesday, August 6, 2008
Shares in Karo Bio AB gained almost 30 percent this week on news that the company's lead drug candidate, the thyroid hormone receptor agonist eprotirome (KB2115) attained the primary endpoints in a Phase IIb trial in patients with elevated blood lipids who already were receiving statins. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription